Back to Search Start Over

Tailored anti-biofilm activity - Liposomal delivery for mimic of small antimicrobial peptide.

Authors :
Hemmingsen LM
Giordani B
Paulsen MH
Vanić Ž
Flaten GE
Vitali B
Basnet P
Bayer A
Strøm MB
Škalko-Basnet N
Source :
Biomaterials advances [Biomater Adv] 2023 Feb; Vol. 145, pp. 213238. Date of Electronic Publication: 2022 Dec 13.
Publication Year :
2023

Abstract

The eradication of bacteria embedded in biofilms is among the most challenging obstacles in the management of chronic wounds. These biofilms are found in most chronic wounds; moreover, the biofilm-embedded bacteria are considerably less susceptible to conventional antimicrobial treatment than the planktonic bacteria. Antimicrobial peptides and their mimics are considered attractive candidates in the pursuit of novel therapeutic options for the treatment of chronic wounds and general bacterial eradication. However, some limitations linked to these membrane-active antimicrobials are making their clinical use challenging. Novel innovative delivery systems addressing these limitations represent a smart solution. We hypothesized that incorporation of a novel synthetic mimic of an antimicrobial peptide in liposomes could improve its anti-biofilm effect as well as the anti-inflammatory activity. The small synthetic mimic of an antimicrobial peptide, 7e-SMAMP, was incorporated into liposomes (~280 nm) tailored for skin wounds and evaluated for its potential activity against both biofilm formation and eradication of pre-formed biofilms. The 7e-SMAMP-liposomes significantly lowered inflammatory response in murine macrophages (~30 % reduction) without affecting the viability of macrophages or keratinocytes. Importantly, the 7e-SMAMP-liposomes completely eradicated biofilms produced by Staphylococcus aureus and Escherichia coli above concentrations of 6.25 μg/mL, whereas in Pseudomonas aeruginosa the eradication reached 75 % at the same concentration. Incorporation of 7e-SMAMP in liposomes improved both the inhibition of biofilm formation as well as biofilm eradication in vitro, as compared to non-formulated antimicrobial, therefore confirming its potential as a novel therapeutic option for bacteria-infected chronic wounds.<br />Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Marianne H. Paulsen has patent #WO/2018/178198 issued to UiT The Arctic University of Norway. Annette Bayer has patent #WO/2018/178198 issued to UiT The Arctic University of Norway. Morten B. Strom has patent #WO/2018/178198 issued to UiT The Arctic University of Norway.<br /> (Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
2772-9508
Volume :
145
Database :
MEDLINE
Journal :
Biomaterials advances
Publication Type :
Academic Journal
Accession number :
36527962
Full Text :
https://doi.org/10.1016/j.bioadv.2022.213238